198 related articles for article (PubMed ID: 33051476)
21. Nos3 Gene Rs1799983 and Rs2070744 Polymorphisms in Patients with Periodontal Disease.
Mazurek-Mochol M; Kozak M; Sawczuk M; Maciejewska A; Malinowski D; Safranow K; Pawlik A
Folia Biol (Praha); 2018; 64(2):59-64. PubMed ID: 30338757
[TBL] [Abstract][Full Text] [Related]
22. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
Iseda N; Itoh S; Toshida K; Tomiyama T; Morinaga A; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Yoshizumi T; Mori M
Cancer Sci; 2022 Jul; 113(7):2272-2287. PubMed ID: 35466502
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
24. Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia.
He H; Xu YJ; Yin JY; Li X; Qu J; Xu XJ; Liu ZG; Zhou F; Zhai M; Li Y; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):400-7. PubMed ID: 24684492
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
26. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
27. Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer.
Wei W; You Z; Sun S; Wang Y; Zhang X; Pang D; Jiang Y
Mol Carcinog; 2018 Aug; 57(8):988-996. PubMed ID: 29603419
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
29. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
[TBL] [Abstract][Full Text] [Related]
30. Association of the NOS3 Gene Polymorphisms with the Risk of Atopic Dermatitis in Children.
Svitich ОА; Kudryavtseva АV; Slyusareva ЕS; Kravtsova ЕО; Meremianina ЕА; Bystritskaya ЕP; Sobolev VV; Ryabtsev АI; Potapova АB; Zverev VV
Bull Exp Biol Med; 2021 Apr; 170(6):787-790. PubMed ID: 33893961
[TBL] [Abstract][Full Text] [Related]
31. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
Hu W; Huang S; Dong L; Yu C; Li C; Zhang J
Anticancer Drugs; 2019 Mar; 30(3):233-240. PubMed ID: 30779721
[TBL] [Abstract][Full Text] [Related]
32. Association of the NOS3 intron-4 VNTR polymorphism with aneurysmal subarachnoid hemorrhage.
Staalsø JM; Edsen T; Kotinis A; Romner B; Springborg JB; Olsen NV
J Neurosurg; 2014 Sep; 121(3):587-92. PubMed ID: 24972130
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
34. Effects of TNFα, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases.
Basmaci C; Pehlivan M; Tomatir A; Sever T; Okan V; Yilmaz M; Oguzkan-Balci S; Pehlivan S
Asian Pac J Cancer Prev; 2016; 17(3):1009-14. PubMed ID: 27039718
[TBL] [Abstract][Full Text] [Related]
35. Gene-Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril.
Oliveira-Paula GH; Luizon MR; Lacchini R; Fontana V; Silva PS; Biagi C; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):284-291. PubMed ID: 27696692
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Jin Z; Liu H; Han Q; Lv Y; Liu Z
Oncotarget; 2016 May; 7(18):26168-80. PubMed ID: 27034168
[TBL] [Abstract][Full Text] [Related]
38. NOS3 gene variants and male infertility: Association of 4a/4b with oligoasthenozoospermia.
Vučić NLJ; Nikolić ZZ; Vukotić VD; Tomović SM; Vuković II; Kanazir SD; Savić-Pavićević DLJ; Brajušković GN
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28466478
[TBL] [Abstract][Full Text] [Related]
39. PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study.
Yamamoto M; Kobayashi T; Mashima H; Miki D; Kuroda S; Hamaoka M; Aikata H; Chayama K; Ohdan H
Int J Surg; 2020 Aug; 80():84-90. PubMed ID: 32615319
[TBL] [Abstract][Full Text] [Related]
40. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
